Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mitoxantrone hydrochloride
Drug ID BADD_D01481
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status approved; investigational
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D02166
MeSH ID D008942
PubChem ID 51082
TTD Drug ID D0R3JB
NDC Product Code 58598-0005; 63323-132
UNII U6USW86RD0
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H30Cl2N4O6
CAS Registry Number 70476-82-3
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Seizure17.12.03.001--
Sepsis11.01.11.003--
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Skin infection11.01.12.003; 23.11.04.007--
Stomatitis07.05.06.005--
Tachycardia02.03.02.007--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.001--
Ventricular arrhythmia02.03.04.006--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Ejection fraction decreased13.14.02.003--
Contusion15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001--
Infusion site phlebitis24.12.03.002; 12.07.05.004; 08.02.05.003--Not Available
Haemorrhage24.07.01.002--Not Available
Blood alkaline phosphatase abnormal13.04.02.005--Not Available
Antineutrophil cytoplasmic antibody decreased13.06.01.010--Not Available
Neurological symptom17.02.05.010--Not Available
Bladder disorder20.03.01.002--Not Available
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Urine analysis abnormal13.13.02.008--Not Available
Transaminases abnormal13.03.04.034--Not Available
CD4 lymphocytes abnormal13.01.06.035--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages